Please Wait.....
Report
Asia-Pacific Vaccines Market - Industry Trends and Forecast to 2030
Market Report I 2023-02-01 I 268 Pages I Data Bridge Market Research
Asia-Pacific vaccines market is projected to register a CAGR of 9.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation:
Asia-Pacific Vaccines Market, By Composition (Combination Vaccines and Mono Vaccines), Type (Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, and Toxoid Vaccines), Kind (Routine Vaccine, Recommended Vaccine, and Required Vaccine), Age of Administration (Pediatric Vaccine and Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps & Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, and Others), Route of Administration (Injectable, Oral, and Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, and Rest of Asia-Pacific) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the vaccines market are:
- Growing immunization programs and campaigns
- Improvement in treatment
- Launch of newer vaccines
Market Players:
The key market players for Asia-Pacific vaccines market are listed below:
- Abbott
- ALK
- AstraZeneca
- BAXTER VACCINES (A Subsidiary of Baxter)
- Bharat Biotech
- Bio Farma
- Biological E Limited
- DAIICHI SANKYO COMPANY, LIMITED
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc.
- Janssen Global Services, LLC (A Subsidiary of Johnson & Johnson Services, Inc.)
- Lanzhou Biological Products Research Institute Co., Ltd.
- Merck sharp & Dohme corp. (A Subsidiary of Merck & Co., Inc.)
- Panacea Biotec Ltd
- Pfizer Inc.
- Sanofi
- Seqirus (A Subsidiary of CSL Limited)
- Serum Institute of India Pvt. Ltd.
- Takeda Pharmaceutical Company Limited
TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE ASIA-PACIFIC VACCINES MARKET 24
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 27
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 CURRENCY AND PRICING 31
2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
2.6 MULTIVARIATE MODELLING 35
2.7 COMPOSITION LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 SECONDARY SOURCES 40
2.11 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHT 45
4.1 PESTEL MODEL 45
4.2 PORTER'S FIVE FORCES 46
4.3 EPIDEMIOLOGY 47
4.4 INDUSTRIAL INSIGHTS: 48
4.5 PIPELINE ANALYSIS 50
4.6 ASIA-PACIFIC VACCINES MARKET: SUPPLY CHAIN MANAGEMENT OF VACCINES 55
4.6.1 COLD CHAIN STORAGE: 56
4.6.2 PROCESS OF LOGISTICS 58
5 REGULATORY FRAMEWORK 60
5.1 JAPAN 60
5.2 CHINA 61
5.3 SOUTH KOREA 61
5.4 INDIA 61
5.5 AUSTRALIA 62
5.6 SINGAPORE 63
5.7 THAILAND 64
5.8 MALAYSIA 64
5.9 INDONESIA 64
5.10 VIETNAM 65
5.11 PHILIPPINES 66
5.12 REST OF ASIA-PACIFIC 66
5.12.1 TAIWAN 67
5.12.2 CAMBODIA 68
6 MARKET OVERVIEW 69
6.1 DRIVERS 71
6.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS 71
6.1.2 HIGH PREVALENCE OF CHRONIC CONDITIONS SUCH AS FLU, INFECTIOUS AND VIRAL DISEASES 71
6.1.3 IMPROVEMENT IN TREATMENT 72
6.1.4 LAUNCH OF NEWER VACCINES 72
6.1.5 INCREASING GOVERNMENT SUPPORT 73
6.2 RESTRAINTS 73
6.2.1 UNAVAILABILITY OF REGISTERED VACCINES 73
6.2.2 DIFFICULTIES ASSOCIATED WITH THE TRANSPORT AND PRODUCTION OF VACCINES 74
6.3 OPPORTUNITIES 74
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 74
6.3.2 PRESENCE OF PIPELINE PRODUCTS 75
6.3.3 RISE IN EXPENDITURE IN THE HEALTHCARE SECTOR 76
6.3.4 INCREASING AWARENESS FOR VACCINATION 77
6.4 CHALLENGES 77
6.4.1 SIDE EFFECTS CAUSED BY VACCINES 77
6.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS 78
6.4.3 PRODUCT RECALL 78
7 ASIA-PACIFIC VACCINES MARKET, BY COMPOSITION 80
7.1 OVERVIEW 81
7.2 COMBINATION VACCINES 84
7.3 MONO VACCINES 84
8 ASIA-PACIFIC VACCINES MARKET, BY TYPE 85
8.1 OVERVIEW 86
8.2 SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES 89
8.2.1 PNEUMOCOCCAL DISEASE 90
8.2.2 HIB (HAEMOPHILUS INFLUENZA TYPE B) DISEASE 90
8.2.3 HPV (HUMAN PAPILLOMA VIRUS) 90
8.2.4 HEPATITIS B 90
8.2.5 MENINGOCOCCAL 90
8.2.6 SHINGLES 90
8.2.7 WHOOPING COUGH 90
8.2.8 OTHERS 90
8.3 LIVE-ATTENUTAED VACCINES 90
8.3.1 ROTAVIRUS 91
8.3.2 MEASLES 91
8.3.3 MUMPS 91
8.3.4 RUBELLA 91
8.3.5 SMALLPOX 91
8.3.6 YELLOW FEVER 91
8.3.7 OTHERS 92
8.4 INACTIVATED VACCINES 92
8.4.1 FLU (SHOT ONLY) 92
8.4.2 POLIO (SHOT ONLY) 92
8.4.3 HEPATITIS A 93
8.4.4 RABIES 93
8.4.5 OTHERS 93
8.5 TOXOID VACCINES 93
8.5.1 DIPHTHERIA, TETANUS & PERTUSSIS (DTP) 94
8.5.2 OTHERS 94
9 ASIA-PACIFIC VACCINES MARKET, BY KIND 95
9.1 OVERVIEW 96
9.2 ROUTINE VACCINES 99
9.2.1 PNEUMOCOCCAL DISEASES 99
9.3 DIPTHERIA, TETANUS & PERTUSIS(DPT) 100
9.3.1 HIB (HAEMOPHILUS INFLUENZA TYPE B) DISEASE 100
9.3.2 MEASLES 100
9.3.3 MUMPS 100
9.3.4 HEPATITIS B 100
9.3.5 RUBELLA 100
9.3.6 POLIO 100
9.3.7 OTHERS 100
9.4 RECOMMENDED VACCINE 100
9.4.1 TYPHOID FEVER VACCINE 101
9.5 HEPATITIS A 101
9.5.1 RABIES 101
9.5.2 JAPANESE ENCEPHALITIS 101
9.5.3 TICK-BORNE ENCEPHALITIS 102
9.5.4 CHOLERA 102
9.5.5 OTHERS 102
9.6 REQUIRED VACCINE 102
9.6.1 MENINGOCOCCAL 103
9.7 YELLOW FEVER 103
9.7.1 OTHERS 103
10 ASIA-PACIFIC VACCINES MARKET, BY AGE OF ADMINISTRATION 104
10.1 OVERVIEW 105
10.2 PEDIATRIC VACCINE 108
10.2.1 PNEUMOCOCCAL DISEASES 109
10.3 MEASLES, MUMPS & RUBELLA 109
10.3.1 DIPTHERIA, TETANUS & PERTUSIS (DPT) 109
10.3.2 ROTAVIRUS 109
10.3.3 MENINGOCOCCAL 109
10.3.4 VARICELLA 109
10.3.5 POLIO 109
10.3.6 TUBERCULOSIS 109
10.3.7 MALARIA 109
10.3.8 OTHERS 109
10.4 ADULT VACCINE 110
10.4.1 INFLUENZA 111
10.5 HPV (HUMAN PAPILLOMA VIRUS) 111
10.5.1 TYPHOID 111
10.5.2 HEPATITIS B 111
10.5.3 JAPANESE ENCEPHALITIS 111
10.5.4 YELLOW FEVER 111
10.5.5 CANCER 111
10.5.6 OTHERS 111
11 ASIA-PACIFIC VACCINES MARKET, BY DISEASES 112
11.1 OVERVIEW 113
11.2 PNEUMOCCOCAL DISEASE 116
11.3 MEASLES, MUMPS & RUBELLA 116
11.4 DPT 117
11.5 HEPATITIS 117
11.6 INFLUENZA 117
11.7 TYPHOID 118
11.8 MENINGOCOCCAL 118
11.9 VARICELLA 119
11.10 RABIES 119
11.11 JAPANESE ENCEPHALITIS 119
11.12 YELLOW FEVER 120
11.13 OTHERS 120
12 ASIA-PACIFIC VACCINES MARKET, BY ROUTE OF ADMINISTRATION 121
12.1 OVERVIEW 122
12.2 INJECTABLE 125
12.2.1 INTRAMUSCULAR 125
12.2.2 SUBCUTANEOUS 125
12.2.3 INTRADERMAL 125
12.3 ORAL 126
12.4 NASAL 126
13 ASIA-PACIFIC VACCINES MARKET, BY END USER 127
13.1 OVERVIEW 128
13.2 COMMUNITY HOSPITALS 131
13.3 HOSPITALS 131
13.4 SPECIALTY CENTERS 131
13.5 CLINICS 132
13.6 OTHERS 132
14 ASIA-PACIFIC VACCINES MARKET, BY DISTRIBUTION CHANNEL 133
14.1 OVERVIEW 134
14.2 HOSPITAL PHARMACY 137
14.3 RETAIL PHARMACY 137
14.4 ONLINE PHARMACY 138
15 ASIA-PACIFIC VACCINE MARKET 139
15.1 ASIA-PACIFIC 139
15.1.1 JAPAN 144
15.1.2 CHINA 150
15.1.3 AUSTRALIA 156
15.1.4 INDIA 162
15.1.5 SOUTH KOREA 168
15.1.6 SINGAPORE 175
15.1.7 MALAYSIA 181
15.1.8 THAILAND 187
15.1.9 INDONESIA 193
15.1.10 PHILIPPINES 199
15.1.11 VIETNAM 205
15.1.12 REST OF ASIA PACIFIC 211
16 ASIA-PACIFIC VACCINES MARKET: COMPANY LANDSCAPE 212
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 212
16.2 DISEASE SHARE ANALYSIS: PFIZER, INC. 213
16.3 COUNTRY SHARE ANALYSIS: PFIZER, INC. 214
16.4 DISEASE SHARE ANALYSIS: MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) 215
16.5 COUNTRY SHARE ANALYSIS: MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) 216
16.6 DISEASE SHARE ANALYSIS: GLAXOSMITHKLINE PLC 217
16.7 COUNTRY SHARE ANALYSIS: GLAXOSMITHKLINE PLC. 218
16.8 DISEASE SHARE ANALYSIS: SANOFI 219
16.9 COUNTRY SHARE ANALYSIS: SANOFI 220
16.10 DISEASE SHARE ANALYSIS: SERUM INSTITUTE OF INDIA PVT. LTD. 221
16.11 COUNTRY SHARE ANALYSIS: SERUM INSTITUTE OF INDIA PVT. LTD. 222
17 SWOT ANALYSIS 223
18 COMPANY PROFILE 224
18.1 PFIZER INC. 224
18.1.1 COMPANY SNAPSHOT 224
18.1.2 REVENUE ANALYSIS 224
18.1.3 PRODUCT PORTFOLIO 225
18.1.4 RECENT DEVELOPMENTS 225
18.2 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) 226
18.2.1 COMPANY SNAPSHOT 226
18.2.2 REVENUE ANALYSIS 226
18.2.3 COMPANY WEBSITE AND PRESS RELEASES 226
18.2.4 PRODUCT PORTFOLIO 227
18.2.5 RECENT DEVELOPMENTS 227
18.3 GLAXOSMITHKLINE PLC. 229
18.3.1 COMPANY SNAPSHOT 229
18.3.2 REVENUE ANALYSIS 229
18.3.3 PRODUCT PORTFOLIO 230
18.3.4 RECENT DEVELOPMENTS 231
18.4 SANOFI 232
18.4.1 COMPANY SNAPSHOT 232
18.4.2 REVENUE ANALYSIS 232
18.4.3 PRODUCT PORTFOLIO 233
18.4.4 RECENT DEVELOPMENTS 233
18.5 SERUM INSTITUTE OF INDIA PVT. LTD. 234
18.5.1 COMPANY SNAPSHOT 234
18.5.2 PRODUCT PORTFOLIO 234
18.5.3 RECENT DEVELOPMENTS 236
18.6 ABBOTT 237
18.6.1 COMPANY SNAPSHOT 237
18.6.2 REVENUE ANALYSIS 237
18.6.3 PRODUCT PORTFOLIO 238
18.6.4 RECENT DEVELOPMENTS 238
18.7 ASTRAZENECA (2022) 239
18.7.1 COMPANY SNAPSHOT 239
18.7.2 REVENUE ANALYSIS 239
18.7.3 PRODUCT PORTFOLIO 240
18.7.4 RECENT DEVELOPMENTS 240
18.8 ALK 241
18.8.1 COMPANY SNAPSHOT 241
18.8.2 REVENUE ANALYSIS 241
18.8.3 PRODUCT PORTFOLIO 242
18.8.4 RECENT DEVELOPMENTS 242
18.9 BAXTER VACCINES (A SUBSIDIARY OF BAXTER) 243
18.9.1 COMPANY SNAPSHOT 243
18.9.2 REVENUE ANALYSIS 243
18.9.3 PRODUCT PORTFOLIO 244
18.9.4 RECENT DEVELOPMENT 244
18.10 BHARAT BIOTECH 245
18.10.1 COMPANY SNAPSHOT 245
18.10.2 PRODUCT PORTFOLIO 245
18.10.3 RECENT DEVELOPMENTS 246
18.11 BIO FARMA 247
18.11.1 COMPANY SNAPSHOT 247
18.11.2 PRODUCT PORTFOLIO 247
18.11.3 RECENT DEVELOPMENTS 248
18.12 BIOLOGICAL E LIMITED 249
18.12.1 COMPANY SNAPSHOT 249
18.12.2 PRODUCT PORTFOLIO 249
18.12.3 RECENT DEVELOPMENTS 250
18.13 DAIICHI SANKYO COMPANY, LIMITED 251
18.13.1 COMPANY SNAPSHOT 251
18.13.2 REVENUE ANALYSIS 251
18.13.3 PRODUCT PORTFOLIO 252
18.13.4 RECENT DEVELOPMENTS 252
18.14 F. HOFFMANN-LA ROCHE LTD 253
18.14.1 COMPANY SNAPSHOT 253
18.14.2 REVENUE ANALYSIS 253
18.14.3 PRODUCT PORTFOLIO 254
18.14.4 RECENT DEVELOPMENT 254
18.15 JANSSEN GLOBAL SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 255
18.15.1 COMPANY SNAPSHOT 255
18.15.2 REVENUE ANALYSIS 255
18.15.3 PRODUCT PORTFOLIO 256
18.15.4 RECENT DEVELOPMENTS 256
18.16 LANZHOU BIOLOGICAL PRODUCTS RESEARCH INSTITUTE CO., LTD., 257
18.16.1 COMPANY SNAPSHOT 257
18.16.2 PRODUCT PORTFOLIO 257
18.16.3 RECENT DEVELOPMENTS 257
18.17 PANACEA BIOTEC LTD 258
18.17.1 COMPANY SNAPSHOT 258
18.17.2 REVENUE ANALYSIS 258
18.17.3 PRODUCT PORTFOLIO 259
18.17.4 RECENT DEVELOPMENTS 259
18.18 SEQIRUS (A SUBSIDIARY OF CSL LIMITED) 260
18.18.1 COMPANY SNAPSHOT 260
18.18.2 REVENUE ANALYSIS 260
18.18.3 PRODUCT PORTFOLIO 261
18.18.4 RECENT DEVELOPMENTS 261
18.19 TAKEDA PHARMACEUTICAL COMPANY LIMITED 262
18.19.1 COMPANY SNAPSHOT 262
18.19.2 REVENUE ANALYSIS 262
18.19.3 COMPANY WEBSITE AND PRESS RELEASES 263
18.19.4 PRODUCT PORTFOLIO 263
18.19.5 RECENT DEVELOPMENTS 263
19 QUESTIONNAIRE 264
20 RELATED REPORTS 268
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security